HEOR
Damage control: How will pharma manage the health economic impacts of Brexit?
October 23, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HEOR, brexit, health economics and outcomes research, pharma
When it comes to life sciences and patient outcomes, the UK’s destiny is inextricably tied to its relationship with the …
The economics of mental health
October 8, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HEOR, health economics and outcomes research, mental health, pharma
Louis Goss examines mental health from a health economics and outcomes research (HEOR) perspective and asks what might be done …
Researchers question price of GSK’s Nucala
December 23, 2015Research and Development GSK, HEOR, ICER, Nucala, asthma, cost-effective, health economics, health economics outcomes research
GSK is charging up to four times more for its recently approved asthma drug Nucala than is justified by cost-effectiveness …
Novo Nordisk looks to HEOR data to back Victoza
November 11, 2015Research and Development, Sales and Marketing Byetta, HEOR, Lyxumia, NHS, Novo Nordisk, Victoza, cost-effectiveness
A Novo Nordisk-sponsored study of the cost-effectiveness of three different injectable anti-diabetes drugs has found Victoza is a cheaper option …
Health Economics and Outcomes Research – What’s the Value?
July 2, 2012Medical Communications HEOR, clinical evidence, economic evidence, market access, value
Pricing pressure and regulatory restrictions across various healthcare industries have called for more detailed evidence of outcomes
Measuring Return on Investment of Health Economics and Outcomes Research through the Cloud
July 2, 2012Medical Communications HEOR, ROI, interactive tools, market access
Health economics and outcomes research (HEOR) is a young and fascinating area of research with an engaged academic community. Methodology …
